 |
|
|
| |
Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) Is Superior to Ritonavir (RTV)-Boosted Atazanavir (ATV) Plus FTC/TDF in Treatment-Naïve Women With HIV-1 Infection (WAVES Study)
|
| |
| |
Reported by Jules Levin
8th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2015, Vancouver, British Columbia, Canada
Kathleen Squires,1 Cissy Kityo,2 Sally Hodder,3 Debbie Hagins,4 Anchalee Avihingsanon,5 Yulia Plotnikova,6 Ellen Koenig,7
Frank Post,8 Shan-Shan Chen,9 Kirsten White,9 Huyen Cao,9 Andrew Cheng,9 Javier Szwarcberg,9 WAVES Study Investigators
1Thomas Jefferson University, Philadelphia, Pennsylvania, USA; 2Joint Clinical Research Centre, Kampala, Uganda; 3West Virginia University, Morgantown, West Virginia, USA;
4Chatham County Health Dept, Savannah, Georgia, USA; 5The Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 6GUZ Irkutsk Regional Center for Prevention and Control of AIDS and Infectious Diseases, Irkutsk, Russian Federation; 7Zona Universitaria/Instituto Dominicano de Estudios Virologicos, Santo Domingo, Dominican Republic; 8Kings College London, UK; 9Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
